AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03786055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Yoga and Meditation (SYM)
Description: A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
Study NCT00729807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentamidine
Study NCT00581997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study NCT00581997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04781985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: extraction of the bladder stone via suprapubic incision
Study NCT01524185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyLive
Description: Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
Study NCT01524185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mental Health Treatment
Description: Standard trauma-informed mental health treatment
Study NCT01887522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine + Nilotinib
Description: * Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28
Study NCT01887522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: · Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
Study NCT01881165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry
Study NCT01881165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01471353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Plus Capecitabine (SorCape)
Description: Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Study NCT02115165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
Study NCT02818530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOP by tonometer
Description: Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
Study NCT02818530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior chamber depth measurement by ultrasound
Description: Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
Study NCT00932841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One packet PO daily x 8 weeks.
Study NCT00932841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 900 billion bacteria
Description: One packet PO daily, x 8 weeks
Study NCT00932841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 90 billion bacteria
Description: One packet PO daily, x 8 weeks.
Study NCT02760927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube Fastener
Description: The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
Study NCT00012974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)
Study NCT00012974 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Provider education, computer reminders, nurse case management
Study NCT03606174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
Study NCT03606174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study NCT03606174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
Study NCT03606174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Study NCT01547286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standardized Cat Allergen Extract and Standardized Dust Mite Allergen
Description: The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
Study NCT01547286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography imaging, functional Positron Emission Tomography imaging
Description: Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
Study NCT01547286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized methacholine inhalation
Description: Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
Study NCT00574847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
Study NCT00574847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg capsules administered by mouth once daily (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 matched capsules administered by mouth once daily (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT04668963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRROR THERAPY
Description: patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
Study NCT04668963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIRROR THERAPY
Description: patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
Study NCT00424164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study NCT00424164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT02234037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
Study NCT02234037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
Study NCT03560076 — intervention group
Intervention type: OTHER
Intervention: SBIRT Training and Implementation Strategies
Description: A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
Study NCT00424164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone (or equivalent)
Description: 100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study NCT01855750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or equivalent)
Description: 100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study NCT01298466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
Study NCT02649647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resection
Description: The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
Study NCT02649647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximally extended resection
Description: The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
Study NCT03312166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression device
Description: interventions on patient are :~* surgical excision of ear lobe keloid~* application of compression device on sutured skin
Study NCT02993900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image-Guided Brachytherapy
Description: Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
Study NCT03006575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
Study NCT03006575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study NCT03270488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser (power of 3.0w).
Study NCT03270488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Laser (power 0,0w)
Study NCT02154659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 24hr pH monitoring
Study NCT03977688 — intervention group
Intervention type: DEVICE
Intervention: Cytokin Adsorption
Description: Haemadsorption with Cytokin Adsorber (Cytosorb)
Study NCT03630887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WarmTouch Model 5900, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied in the preanesthetic room during different time periods.
Study NCT00875901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Peripherally located lung tumor
Description: 12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
Study NCT00875901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Centrally located lung tumor
Description: 6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
Study NCT02282384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
Study NCT02282384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05264584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Study NCT05264584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isotonic saline
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Study NCT05264584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
Study NCT05264584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetyl cysteine
Description: all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
Study NCT05264584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 MG
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Study NCT00632970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 1, 400mg tablet twice a day, with Truvada 1 tablet once a day
Study NCT00632970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 2 tablets twice a day, with Truvada 1 tablet once a day
Study NCT00632970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: 1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
Study NCT00632970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: 1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
Study NCT03180502 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT (Intensity-Modulated Radiation Therapy)
Description: Undergo IMRT
Study NCT03180502 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT03180502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Chemotherapy drug
Study NCT03180502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Chemotherapy drug
Study NCT03650608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: HL217 Ophathalmic Solution QD
Description: Cohort 1 (Once a day)
Study NCT02363400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEP
Description: Adjuvant Chemotherapy
Study NCT01554215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom Power Intervention Group
Description: attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
Study NCT01554215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mom Power Attentional Control Group
Description: at home control, weekly mailings
Study NCT01113528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative therapy (omega 3 PUFA plus low dose aspirin)
Description: Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
Study NCT01113528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 3 times daily
Study NCT01211691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB004, Monoclonal Antibody
Study NCT05149066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #KindGirlsInACTion
Description: 9-session weekly cognitive-behavioural intervention to promote psychological well-being and prevent body image and eating-related disordered behaviours.
Study NCT00681798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: 100mg/300mg
Study NCT02984098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
Study NCT02984098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
Study NCT02984696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg of transdermal estradiol daily and 10mg of oral MPA
Study NCT01602939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine and pegylated interpheron alpha-2a
Description: Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months.